Clinical Controlled Trial to Determinate the Role of Sodium Bicarbonate in the Prevention of Contrast-Induced Nephropathy in High-Risk Patients Undergoing to Diagnostic Coronariography and/or Percutaneous Coronary Intervention
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Acute Kidney Failure
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
- Enrollment
- 100
- Locations
- 2
- Primary Endpoint
- Contrast-induced nephropathy
- Last Updated
- 19 years ago
Overview
Brief Summary
The purpose of this study is to determine whether sodium bicarbonate is effective in the prevention of sodium-induced nephropathy
Detailed Description
The use of contrast media is more frequent as new diagnostic and therapeutic procedures are developed. As a consequence, the occurrence of acute renal failure (ARF), also known as contrast-induced nephropathy, is more frequently seen after the realization of these procedures, representing about 10% of all in-hospital ARF. The importance of preventing this complication is related with its strong association with higher morbidity and mortality rates in patients who present it. A number of drugs and interventions have been studied for preventing contrast-induced nephropathy, including intravenous hydration with normal and hypotonic saline solutions, oral hydration, mannitol, diuretics, dopamine and its antagonists (fenoldopam), calcium antagonists, theophylline, N-acetylcysteine, natriuretic atrial peptide and hemodialysis after or during contrast media administration. There is only one study in humans that demonstrates the utility of the sodium bicarbonate to prevent the contrast-induced nephropathy, showing a reduction in the incidence of this complication of about 13.6%. Although this result could seem convincing, its relevance has been questioned because the definition used by the authors as contrast-induced nephropathy was an increase of 25% from basal creatinine. Although when compared, the absolute differences between basal and after-procedure creatinines were not statistically significative, the sample size was small and the participants were low-risk patients to develop contrast-induced nephropathy. It is also important to note that the control group was hydrated with a dextrose 5% solution with 154 mEq of NaCl, although today's most accepted prevention therapy is intravenous hydration with normal saline solution. Comparison: Hydration previously, during and afterwards contrast media administration with normal saline solution (0.9%), compared to hydration previous, during and afterwards contrast media administration with a solution made of normal saline and sodium bicarbonate.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age over 18 years old
- •Indication for coronariography and/or percutaneous coronary intervention
- •Voluntary written consent for the realization of coronariography and/or percutaneous intervention and for the participation in this clinical trial
- •A MEHRAN contrast-induced nephropathy score of six or more
Exclusion Criteria
- •Patients with chronic kidney failure requiring any kind of dialysis
- •Patients unable to complete follow-up
- •Multiple myeloma
- •Exposure to contrast 48 hours prior to study
- •Pregnancy
- •Patients unable to give consent
- •Already receiving sodium bicarbonate solutions
- •Receiving contrast media other than non-ionic
Outcomes
Primary Outcomes
Contrast-induced nephropathy
Secondary Outcomes
- Hemodialysis